Directorate Change
Thursday October 25, 2018
Thursday October 25, 2018
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Destiny Pharma plc
(“Destiny Pharma” or “the Company”)
Directorate Change
Destiny Pharma appoints Shaun Claydon as Chief Financial Officer
Brighton, United Kingdom – 25 October 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, which address the global problem of antimicrobial resistance (AMR), today announces the appointment of Shaun Claydon to the Board as the Company’s Chief Financial Officer (CFO) and Company Secretary with immediate effect. Shaun succeeds Simon Sacerdoti who has chosen to step down as CFO, Company Secretary, and a member of the Board to pursue other business opportunities. Mr Sacerdoti, having successfully helped the Company through its successful Initial Public Offering on AIM in 2017, will remain an employee of Destiny Pharma until the end of the year to ensure an orderly handover, at which point he will continue to assist the Board in a consultancy capacity.
Mr Claydon is an accomplished corporate financier and Chartered Accountant with over 16 years board level experience within the biotechnology sector. He has extensive experience of delivering financial and operating results and recently served as CFO of Creabilis, a venture backed clinical stage specialty pharmaceutical company focused on dermatology treatments, during which he led a $150 million sale of the business to Sienna Biopharmaceuticals.
Prior to that he was CFO and Chief Operating Officer (COO) of Orteq Sports Medicine, a medical device company and world leader in the field of biodegradable polymer technologies. Mr Claydon was also responsible for origination and execution of domestic and international mergers and acquisitions as a director in HSBC’s Investment Banking division. Mr Claydon holds a BA in Economics from the University of Leeds, UK.
Sir Nigel Rudd, Chairman of Destiny Pharma, commented:
“On behalf of the Board, I wish to express our gratitude to Simon for his valuable contribution to Destiny Pharma over the past three years, including being an integral member of the team to execute a successful IPO last year. We are pleased to welcome Shaun to Destiny Pharma. His broad and relevant biotechnology sector experience as both CFO and COO will prove invaluable to the Company as we execute our clinical strategy and next stages of growth.”
The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Shaun Claydon, aged 50, has been a director of the following companies during the five years preceding the date of this announcement:
|
Current directorships |
Past directorships |
|
Distil plc |
Orteq Limited |
|
|
Orteq Inc |
Save as set out above there are no further disclosures pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.
Mr Claydon has no beneficial interest in the ordinary shares of the Company.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
pressoffice@destinypharma.com
+44 (0)1273 704 440
FTI Consulting
Simon Conway / Victoria Foster Mitchell
destinypharma@fticonsulting.com
+44 (0) 20 3727 1000
Cantor Fitzgerald Europe (Nominated Adviser and Joint Broker)
Philip Davies / Will Goode, Corporate Finance
Andrew Keith, Healthcare Equity Sales
+44 (0)20 7894 7000
finnCap Ltd (Joint Broker)
Geoff Nash /Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500
About Destiny Pharma
Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development of novel medicines that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life-threatening infections caused by antibiotic-resistant bacteria, often referred to as “superbugs”. Tackling anti-microbial resistance has become a global imperative recognised by the WHO and the United Nations, as well as the G7 and the G20 countries. For further information, please visit https://destinypharma.com